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Abstract
Background Pain management can be challenging in frail
older people with cancer due to drug–drug interactions and
heightened susceptibility to adverse drug events.
Objective To investigate the relationship between anal-
gesic use and pain by frailty status in older outpatients with
cancer.
Methods A total of 385 consecutive patients aged
70 years and over who presented to an outpatient oncology
clinic between January 2009 and July 2010 completed
structured assessments of analgesic use (opioids, parac-
etamol or non-steroidal anti-inflammatory drugs), pain (10-
point visual analogue scale) and clinical factors. Frailty
was derived using modified Fried’s frailty phenotype. Lo-
gistic regression was used to compute adjusted odds ratios
(ORs) and 95 % confidence intervals (CIs) for the rela-
tionship between analgesic use and pain for each frailty
group (robust, pre-frail or frail).
Results For robust outpatients (n = 101), there was weak
evidence for a 30 % relative increase in the adjusted odds
of analgesic use between outpatients who differed by one
unit of pain score (95 % CI 0.995-1.71, p = 0.0532). For
pre-frail outpatients (n = 190), there was evidence for a
negative quadratic relationship (adjusted OR for the
quadratic coefficient: 0.952, 95 % CI 0.910-0.993,
p = 0.0244). For frail outpatients (n = 94), there was an
8 % relative increase in the adjusted odds of analgesic use
between outpatients who differed by one unit of pain score,
but no statistical evidence for association (95 % CI 0.934-
1.26; p = 0.298).
Conclusions These findings can be considered for the
ongoing development of safe, effective strategies for
analgesic use in older outpatients with cancer.
1 Introduction
Pain is highly prevalent in older people and is associated
with depression, falls, poor quality of life, sleep distur-
bance, mobility limitation and decline in physical function
[1, 2]. The prevalence of pain doubles from 2 years to
1 month before death [3]. Up to two-thirds of people with
advanced cancer report pain [4].
It has been recognized that optimizing pain management
in people with cancer requires an individualized approach
which seeks to maximize pain relief but minimize the risk
of adverse drug events (ADEs) [5, 6]. Frailty is a geriatric
syndrome characterized by a decreased homeostatic re-
serve resulting in an increased susceptibility to ADEs [7].
Analgesics are the most common pain management
strategy in older people. However, analgesic prescribing
for frail older people is challenging due to increased
heterogeneity in drug disposition and response, multi-
morbidity and changes in body composition [1]. Analgesic
selection is complicated by the risk drug–drug and drug–
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disease interactions [8]. Analgesics are frequently impli-
cated in ADEs requiring hospitalization [9]. There is
minimal evidence to guide pain management in frail older
people. Additionally, since frailty is associated with co-
morbidity and older age, many frail older people are ex-
cluded from participation in clinical trials of analgesics [7].
Cross-sectional studies have identified an association
between pain and frailty [2, 10]. To our knowledge, only
one previous study has specifically investigated analgesic
use and frailty [2]. In this study, more than 65 % of frail
older people used analgesics but nearly half wanted their
physicians to pay greater attention to pain management. No
previous studies have investigated the association between
analgesic use, pain and frailty in older people with cancer.
This is important because both frailty and analgesic-related
ADEs may be exacerbated by cancer and chemotherapy. A
patient’s first presentation to a geriatric oncology outpa-
tient clinic represents an opportunity to optimize pain
management.
The objective of this study was to investigate and
characterize the relationship between analgesic use and
pain by frailty status in older outpatients with cancer. We
expected a higher prevalence of pain among outpatients
who were frail, but a less pronounced relationship between
analgesic use and pain level due to clinicians being re-
luctant to prescribe analgesics to people perceived to be at
high risk of adverse drug events. This knowledge is im-
portant for developing safe and effective strategies for
analgesic use in these outpatients.
2 Methods
2.1 Study Population and Data Collection
The study participants and data collection have been de-
scribed previously [11]. All patients aged 70 years and
over who presented at the medical oncology outpatient
clinic at the Royal Adelaide Hospital between January
2009 and July 2010 completed a structured data collection
instrument.
The instrument captured each participant’s age, sex,
diagnoses, medications, general pain (10-point visual ana-
logue scale, VAS), instrumental activities of daily living
(IADLs [12]), Karnofsky Performance Scale (KPS [13])
physical function (SF-36 [14]), self-reported weight loss
over the past 6 months, exhaustion [15, 16] and distress
(via a 10-point VAS [17]). The instrument was completed
by the outpatient with or without involvement from a
family member, and any sections that were incomplete
were completed with a nurse at their first visit to the clinic.
Self-reported medication use was verified at the first
visit by a nurse with access to each outpatient’s medical
records, and any medications that were not self-reported
were recorded. Data about prescription, non-prescription
and complementary and alternative medications (CAMs)
were collected separately to ensure a full history was ob-
tained. The validity of the medication lists was estimated
by comparing a sample of 30 medication lists to those
obtained by clinical pharmacist interviews. There was a
greater than 70 % concordance overall, with approximately
80 % concordance for prescription medications [18]. This
level of concordance is comparable to medication histories
routinely used in hospital wards [19].
2.2 Measures and Definitions
Medications were coded using the Anatomical Therapeutic
Chemical (ATC) Codes [20]. Analgesics were defined as
opioids (buprenorphine, codeine ? paracetamol, dextro-
propoxyphene, fentanyl, methadone, morphine, oxycodone
and tramadol), paracetamol and non-steroidal anti-inflam-
matory drugs (NSAIDs; celecoxib, diclofenac, ibuprofen,
ibuprofen ? codeine, indomethacin, meloxicam and
naproxen). Analgesic use was defined as use of one or more
of these medications.
Frailty was defined using a modified version of Fried’s
frailty phenotype [15, 21, 22] which considered five cri-
teria: dependence in at least one IADL, weight loss of
[5 % over the past 6 months, an exhaustion score of at
least three, KPS\70 % and dependence in at least one SF-
36 physical function domain. Outpatients were classed as
robust if they had none of the criteria, pre-frail if they had
one or two of the criteria and frail if they had C3 of the
criteria.
2.3 Statistical Analysis
Demographic and clinical characteristics were summarized
numerically and graphically by frailty status (robust, pre-
frail or frail). Logistic regression was used to compute
unadjusted and adjusted odds ratios (ORs) and 95 % con-
fidence intervals (95 % CIs) for the relationship between
analgesic use and pain score for each frailty group
separately. The analyses were adjusted for age, Charlson’s
Comorbidity Index (CCI) and sex. The analyses were
performed in the R statistical package [23]. Results were
interpreted as suggested by Sterne et al. [24].
2.4 Ethical Considerations
The study was approved by the Royal Adelaide Hospital
Human Research Ethics Committee, the University of
South Australia Human Research Ethics Committee and
the Monash University Human Research Ethics committee
[11].
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3 Results
Of 413 consecutive outpatients, 385 completed the data
collection instrument in full. Robust, pre-frail and frail
outpatients had a median age of 77, 75 and 78 years, re-
spectively; 65, 54 and 62 % being male. Robust, pre-frail
and frail outpatients used a median of four, five and seven
medications, respectively. All frailty groups had a median
CCI of 1.
Outpatients who were frail had higher pain scores
(Fig. 1; medians of 1, 2 and 5 for robust, pre-frail and frail
outpatients, respectively) and had a higher prevalence of
analgesic use (corresponding percentages of 21, 34 and
53 %; Fig. 1). Analgesic users who were frail used more
medications (medians of six, eight and nine for robust, pre-
frail and frail outpatients who used analgesics, respec-
tively). Of the analgesic users in the robust group (n = 21),
five (24 %) used an opioid, 14 (67 %) used paracetamol,
five (24 %) used an NSAID and three (14 %) used more
than one analgesic. Of the analgesic users in the pre-frail
group (n = 65), 32 (49 %) used an opioid (most commonly
oxycodone; n = 15), 44 (68 %) used paracetamol, 18
(28 %) used an NSAID (most commonly celecoxib;
n = 15) and 30 (46 %) used more than one analgesic. Of
the analgesic users in the frail group (n = 50), 29 (58 %)
used an opioid (most commonly oxycodone; n = 19), 31
(62 %) used paracetamol, four (8 %) used an NSAID and
24 (48 %) used more than one analgesic.
Figure 2 displays the unadjusted relationship between
analgesic use and pain by frailty status. For robust outpa-
tients, there was weak evidence for a 30 % relative in-
crease in the odds of analgesic use between outpatients
who differed by one unit of pain score after adjusting for
age, CCI and sex (95 % CI for the OR 0.995-1.71,
p = 0.0532). For pre-frail outpatients, there was evidence
for a negative quadratic (i.e. concave) relationship between
the log odds of analgesic use and pain (adjusted OR for the
quadratic coefficient: 0.952, 95 % CI 0.910-0.993,
p = 0.0244). For frail outpatients, there was an 8 % rela-
tive increase in the adjusted odds of analgesic use between
outpatients who differed by one unit of pain score, but no
statistical evidence for association (95 % CI 0.934-1.26,
p = 0.298).
4 Discussion
This was the first study to investigate the association be-
tween analgesic use and pain in older outpatients with
cancer. The main findings were that analgesic use increased
linearly with pain in robust and frail outpatients, but there
was a concave relationship between analgesic use and pain
in pre-frail outpatients. There was a graded association
between pain, analgesic and overall medication according
to frailty status. Robust outpatients had a lower prevalence
of pain, analgesic and overall medication use than frail
outpatients.
The magnitude of the positive linear relationship be-
tween analgesic use and pain was most pronounced in the
robust group, which may indicate that clinicians feel that
the benefits of analgesics in robust older people with cancer
outweigh potential risks. For the frail group, this positive
linear relationship was less pronounced, with lesser pre-
scribing of analgesics per unit difference of pain. This may
reflect clinicians’ caution with prescribing analgesics in
this vulnerable group of this cohort. The higher prevalence
of pain in pre-frail and frail outpatients suggests possible
underuse of pharmacological and non-pharmacological
treatment approaches. This is consistent with previous re-


















































Using at least one analgesic
Fig. 1 Distributions of pain score and analgesic use by frailty status
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changes, polypharmacy and multi-morbidity are potential
barriers to effective pain management [25].
Interestingly, the relationship between analgesic use and
pain was concave in the pre-frail group. This may represent
hesitation in prescribing analgesics to pre-frail older people
with cancer experiencing higher levels of pain. These
people may have been susceptible to ADEs, drug–drug
interactions and/or progression to frailty. Recognizing and
treating pain in pre-frail outpatients is important because
pain is associated with depression and can negatively im-
pact quality of life and function [26, 27].
Our study also demonstrated differences in the types of
analgesics prescribed according to frailty status. People
who were robust were more likely to receive NSAIDs
(n = 5, 24 %) and less likely to receive opiates (n = 5,
24 %) when compared to people who were frail (NSAIDs
n = 4, 8 % and opiates n = 29, 58 %). This may reflect
prescribers’ desire to avoid ADEs and drug–drug interac-
tions in frail people. Additionally, people who were pre-
frail had high levels of both NSAIDs (n = 18, 28 %) and
opiates (n = 32, 49 %), reflecting the complexity of
treating pain in this group.
4.1 Strengths and Limitations
Demographic, clinical and medication data were collected
using a structured data collection instrument and verified at
the initial consultation. The measure of pain used in this
study is well established [28] and has been shown to be
valid, reliable and appropriate for overall pain in a clinical
setting [29]. However, since it was a measure of general
pain, we could not assess the prevalence of particular types
of pain, such as neuropathic or musculoskeletal. Never-
theless, this non-discriminatory measure of pain was con-
sistent with our non-discriminatory definition of analgesic
use. The study did not assess the stage of cancer. It is
possible that outpatients with more advanced cancer may
be more likely to be frail, and may experience more pain,
regardless of the analgesic used. We did not distinguish
between regular and as-needed use of analgesics, or in-
vestigate the use of adjuvant therapies or non-pharma-
cological treatments. The study was conducted in a
single outpatient oncology clinic, hence the results may
not be generalizable to other geriatric oncology cohorts.
As this study was cross-sectional, it was not possible to
describe individual outpatient trajectories of analgesic
use over time, and how these trajectories related to pain
and frailty transitions. Thus longitudinal studies are
warranted.
5 Conclusions
In this cohort of older people recently diagnosed with
cancer, analgesic use increased linearly with pain in robust
and frail outpatients, and there was evidence for a concave
relationship between analgesic use and pain in pre-frail
outpatients. Our findings suggest additional strategies are
needed to optimize analgesic use in older outpatients with
cancer, particularly in pre-frail outpatients experiencing
high levels of pain. Future research should investigate the
role of analgesics as part of a comprehensive and high
quality approach to pain management in these outpatients.
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Fig. 2 Unadjusted associations between analgesic use and pain score by frailty status
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